Axon Enterprise (NASDAQ:AXON) Director Jeri Williams Sells 157 Shares

Axon Enterprise, Inc (NASDAQ:AXON) Director Jeri Williams sold 157 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $490.00, for a total value of $76,930.00. Following the completion of the sale, the director directly owned 1,159 shares of the company’s stock, valued at $567,910. This represents a 11.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Axon Enterprise Stock Performance

Shares of AXON stock traded down $6.23 during trading on Thursday, reaching $502.18. The company had a trading volume of 512,564 shares, compared to its average volume of 1,005,583. The firm’s 50 day simple moving average is $524.40 and its two-hundred day simple moving average is $603.77. Axon Enterprise, Inc has a one year low of $396.41 and a one year high of $885.91. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29. The company has a market capitalization of $40.38 billion, a PE ratio of 330.38, a PEG ratio of 10.81 and a beta of 1.46.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The firm had revenue of $796.72 million during the quarter, compared to analysts’ expectations of $755.29 million. During the same quarter in the prior year, the business earned $2.08 earnings per share. The company’s revenue was up 38.5% on a year-over-year basis. Sell-side analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Creative Financial Designs Inc. ADV bought a new stake in shares of Axon Enterprise in the fourth quarter valued at about $28,000. Stone House Investment Management LLC bought a new position in Axon Enterprise during the third quarter valued at about $29,000. New Millennium Group LLC acquired a new position in Axon Enterprise in the 3rd quarter valued at approximately $29,000. Sound Income Strategies LLC lifted its position in shares of Axon Enterprise by 550.0% in the 4th quarter. Sound Income Strategies LLC now owns 52 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 44 shares during the period. Finally, Camelot Portfolios LLC bought a new stake in shares of Axon Enterprise in the 4th quarter worth approximately $30,000. Institutional investors own 79.08% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on AXON. Piper Sandler dropped their target price on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a report on Monday, December 29th. Morgan Stanley lowered their price target on Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Craig Hallum reiterated a “buy” rating and issued a $820.00 price objective on shares of Axon Enterprise in a research note on Wednesday, February 25th. Finally, Robert W. Baird set a $800.00 price objective on Axon Enterprise in a research report on Wednesday, February 25th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Axon Enterprise presently has an average rating of “Moderate Buy” and an average target price of $762.93.

Key Headlines Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Software & Services momentum — Multiple analyst pieces highlight ~40% growth in Axon’s Software & Services in 2025 and rising subscription revenue, which supports recurring-margin upside for the business. Read More.
• Positive Sentiment: Municipal adoption — A $1.97M Decatur, IL grant to upgrade police tech underscores continued municipal demand that drives both hardware and recurring software contracts. Read More.
• Positive Sentiment: Institutional/information flow — Coverage noting interest from funds (e.g., Baron Opportunity Fund mention) and “trending” status can attract buyer attention and liquidity. Read More.
• Neutral Sentiment: Trending / aggregator stories — Multiple Zacks/Yahoo/MarketBeat rundowns raise awareness but are not new fundamental catalysts. Read More.
• Neutral Sentiment: Short-interest reporting glitch — Recent short-interest posts show “0 shares” and NaN changes; this appears to be a data/reporting issue rather than meaningful short-seller pressure.
• Negative Sentiment: Valuation / “priced in” debate — Commentary (Seeking Alpha and others) argues Axon’s strong growth may already be priced into the stock, increasing sensitivity to any growth-miss or multiple compression. Read More.
• Negative Sentiment: Insider sale — Director Erika Nardini sold 198 shares (~$506.58 avg), reducing her stake ~9.2%; small in dollars but often viewed negatively by sentiment-driven traders. Read More.
• Negative Sentiment: Near-term sentiment drag — Media pieces highlighting a recent multi-day slide and market-cap pullback feed skeptical narratives that can pressure the stock in the short term. Read More.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.